Lešnik Samo, Konc Janez, Vodopivec Tina, Čamernik Katja, Karolina Potokar Urška, Legiša Matic
Faculty of Chemistry and Chemical Engineering, University of Maribor, Maribor, Slovenija.
Department of Molecular Modeling, National Institute of Chemistry, Ljubljana, Slovenia.
PLoS One. 2025 May 21;20(5):e0321998. doi: 10.1371/journal.pone.0321998. eCollection 2025.
Deregulated energy metabolism is a hallmark of cancer, characterized by increased glycolytic flux. Cancer-specific modification of 6-phosphofructo-1-kinase (PFK) impairs its ability to regulate the enzyme's activity which increases glycolytic flux. Consequently, excessive cytosolic NADH formation triggers a harmful redox imbalance in cancer cells, which is rapidly neutralized by the formation of lactic acid and superoxide (SOX). To learn more about deregulated glycolysis in cancer cells, a supercomputer used the atomic model of the crystal structure of human PFK1 for virtual screening a database of 4.5 million compounds by docking with the catalytic binding sites of the enzyme. The screening revealed two compounds capable of reducing modified, cancer-specific PFK1 activity and simultaneously suppressing lactate and SOX formation. A dose-dependent inhibition was observed in the cells treated by compounds in the following tumorigenic cells: Jurkat (Acute T cells leukemia); Caco-2 (colorectal adenocarcinoma); COLO 829 (melanoma); and MDA-MB-231 (breast gland adenocarcinoma). In addition, two selected compounds assessed for cytostatic and cytotoxic activity showed no negative effects on tumorigenic cells. However, during incubation, the strengths of inhibitions continuously decreased, both during lactate and SOX formation. No such effects were observed if compounds were sequentially submitted to the cells at low concentrations every 24 hours. Additional experiments performed by Jurkat cells revealed reduced respiration and glycolysis rates in the cells treated with compounds concerning the untreated cells. Inhibition of modified cancer-specific PFK1 activity reduces deregulated glycolytic flux, prevents abundant cytosolic NADH formation, and restores redox balance thus simultaneously preventing the formation of deleterious effects of lactate and SOX, two crucial players in cancer initiation and development.
能量代谢失调是癌症的一个标志,其特征是糖酵解通量增加。6-磷酸果糖-1-激酶(PFK)的癌症特异性修饰会损害其调节酶活性的能力,从而增加糖酵解通量。因此,过量的胞质NADH形成会在癌细胞中引发有害的氧化还原失衡,而这种失衡会通过乳酸和超氧化物(SOX)的形成迅速得到中和。为了更多地了解癌细胞中失调的糖酵解,一台超级计算机利用人PFK1晶体结构的原子模型,通过与该酶的催化结合位点对接,对一个包含450万种化合物的数据库进行虚拟筛选。筛选发现了两种能够降低修饰的、癌症特异性PFK1活性并同时抑制乳酸和SOX形成的化合物。在以下致瘤细胞中用这些化合物处理的细胞中观察到了剂量依赖性抑制:Jurkat(急性T细胞白血病);Caco-2(结肠直肠腺癌);COLO 829(黑色素瘤);以及MDA-MB-231(乳腺腺癌)。此外,对两种选定化合物的细胞生长抑制和细胞毒性活性评估显示,它们对致瘤细胞没有负面影响。然而,在孵育过程中,无论是在乳酸还是SOX形成过程中,抑制强度都持续下降。如果每隔24小时以低浓度将化合物依次加入细胞中,则未观察到这种影响。Jurkat细胞进行的额外实验显示,与未处理的细胞相比,用化合物处理的细胞呼吸和糖酵解速率降低。抑制修饰的癌症特异性PFK1活性可降低失调的糖酵解通量,防止大量胞质NADH形成,并恢复氧化还原平衡,从而同时防止乳酸和SOX这两种在癌症发生和发展中起关键作用的有害物质的形成。